Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Today’s news reports include items on: Risk for prostate cancer Patient decisions about sexual functionality and prostate cancer treatment Whole gland and focal cryotherapy Testosterone replacement after prostate cancer therapy and other items.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: cryotherapy, decision process, focal, patient, risk, sexual function, testosterone replacement, Trelstar, TRT, UroCool™ | Leave a Comment »
One of the problems every patient faces in making decisions about prostate cancer therapy is, “Who do you believe?”
Filed under: Management, Prevention, Risk, Treatment | 5 Comments »
A recently published study has suggested the possibility of an association between the aggressiveness of prostate cancer and degree of glycemic control in some patients with an existing diagnosis of diabetes.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: aggressiveness, diabetes, glycemic control, HbA1c | Leave a Comment »
This weekend’s news includes items on: The ongoing major prostate cancer screening trials The changing landscape of first-line management for early stage, low risk prostate cancer Outcomes of RALP procedures in which surgical fellows participate Hypofractionation procedures in radiotherapeutic treatment The current state of sexual rehabilitation post-prostatectomy
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, focal therapy, hypofractionation, outcomes, RALP, screening, sexual rehabilitation, training, trials | 2 Comments »
Once upon a time … in a land not so far away … as a perfect sun shone down from a perfect sky … Mr. Bear was ambling quietly across a little used bridge to get to the other side of the ravine.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: bear, tale, wise | 2 Comments »
For men with an elevated PSA, one or more prior negative biopsies, and (perhaps) other risk factors, the potential of magnetic resonance imaging (MRI) technology to facilitate the targeting of prostate cancer tumors has long been attractive.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRI | Leave a Comment »
The four reports dealt with in today’s news all relate to accuracy of initial diagnosis based on available data and subsequent prognostic implications:
Filed under: Diagnosis, Risk | Leave a Comment »
The vast majority of prostate cancers diagnosed around the world each year are adenocarcinomas (cancers of glandular tissues). By comparison, there is a tiny percentage of prostate cancers that are sarcomas (cancers of the connective tissues), accounting for probably between 0.1 and 0.2 percent of all prostate cancer diagnoses each year. Prostate sarcomas, unlike prostate [...]
Filed under: Diagnosis, Management, Treatment | Tagged: carcinosarcoma, leiomysarcoma, rhabdomyosarcoma, sarcoma | 3 Comments »
A review by Ang et al. focused on the mechanism of action of abiraterone acetate in prostate cancer was published today in the British Journal of Cancer. This article may be of interest to many in the prostate cancer community. The full text is available on line.
Filed under: Drugs in development | Comments Off
There are a significant number of relatively long-term news items in today’s report. Of most immediate interest to the majority of prostate cancer patients and educators we include reports on: The fact that over 70 percent of cancers thought to be unilateral at biopsy turn out to be bilateral post-surgery (which has implications for focal [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, curcumin, Degarelix, focal therapy, nanoparticles, PROMIS, sexual function, TRAIL | 3 Comments »
It is well known to readers of The “New” Prostate Cancer InfoLink that androgen deprivation therapy (ADT) is a commonly used form of treatment for patients who experience biochemical recurrence (BCR) after first- or second-line therapy. However, as is also well known, the optimal timing of ADT initiation is uncertain, and earlier initiation of ADT [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, anxiety, hormone therapy, HRQOL, quality of life | 3 Comments »
In what certainly appears to be an insightful article in this week’s issue of Lancet Oncology, Dubben has presented a strong argument that attempting to develop trials that will prove (or disprove) the value of screening for prostate cancer in terms of its impact on mortality is simply an impossible task.
Filed under: Diagnosis, Prevention, Risk | Tagged: screening | Leave a Comment »
McDermott and Sanda have just published an assessment of the recent re-analysis of the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4). This is the study that initially demonstrated a modest but significant survival benefit of prostatectomy over watchful waiting. According to the re-analysis of this study, patients allocated to watchful waiting experienced a significantly [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hormone therapy, quality of life, radical prostatectomy, Scandinavian trial, watchful waiting | 4 Comments »
… and this week he’s “Living with incontinence after prostate cancer.”
Filed under: Living with Prostate Cancer | Tagged: Dana, incontinence, Jennings | Comments Off
Search for new and
ongoing trials on the
CTAG PCa web site